References

• Magic mushrooms as medicine. (2023). Alcohol and Drug Foundation. Retrieved May 23, 2026, from https://adf.org.au/insights/magic-mushrooms-medicine/

• Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 36(2), 151–158. https://doi.org/10.1177/02698811211073759

• Ibarra, A. B. (2025, January 2). CA almost legalized psychedelics. Now it’s looking for a test case. CalMatters. https://calmatters.org/health/2025/01/psychedelic-therapies-veterans/

• Martinez, M. (2022, February 15). Psilocybin treatment for major depression effective for up to a year for most patients, study shows. Johns Hopkins Medicine. https://www.hopkinsmedicine.org/news/newsroom/news-releases/2022/02/psilocybin-treatment-for-major-depression-effective-for-up-to-a-year-for-most-patients-study-shows

• Meshkat, S., Malik, G., Zeifman, R. J., Swainson, J., Balachandra, K., Reichelt, A. C., Zhang, Y., Burback, L., Winkler, O., Greenshaw, A., Vermetten, E., Mayo, L. M., Tanguay, R., Jetly, R., & Bhat, V. (2025). Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review. Neuroscience & Biobehavioral Reviews, 173, 106163. https://doi.org/10.1016/j.neubiorev.2025.106163

• U.S. Food & Drug Administration. FDA warns patients and health care providers about 11 potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders. https://www.fda.gov/drugs/human-drug-compounding/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine

• Yu, F., Tafur, J., Moreno, F., & Dahmer, S. (2026). Inaugural year of regulated psilocybin services in Oregon: Safety, motivations, and utilization. Frontiers in Psychiatry, 17. https://doi.org/10.3389/fpsyt.2026.1777387